Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2248 12/10/2020 avelumab (Bavencio) Full

In combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

SMC2265 12/10/2020 siponimod (Mayzent) Full

For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

SMC2281 12/10/2020 lenalidomide (Revlimid) Full

In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated Follicular Lymphoma (Grade 1 - 3a).

SMC2304 12/10/2020 daratumumab (Darzalex) Abbreviated

As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

SMC2290 12/10/2020 carfilzomib (Kyprolis) Resubmission

In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

SMC2278 12/10/2020 meropenem/vaborbactam (Vaborem) Full

For the treatment of the following infections in adults:

  • Complicated urinary tract infection (cUTI), including pyelonephritis
  • Complicated intra-abdominal infection (cIAI)
  • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

The treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

SMC2289 12/10/2020 lenalidomide (Revlimid) Full

As monotherapy is indicated in multiple myeloma (MM) for the maintenance treatment of adult patients with newly diagnosed MM who have undergone autologous stem cell transplantation (ASCT).

SMC2259 12/10/2020 ibrutinib (Imbruvica) Full

In combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia.

SMC2286 12/10/2020 cerliponase alfa (Brineura) Ultra-orphan initial assessment

For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

SMC2301 12/10/2020 daratumumab (Darzalex) Abbreviated

In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

SMC2158 12/10/2020 budesonide (Jorveza) Full

For the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).

SMC2287 07/09/2020 semaglutide (Rybelsus) Abbreviated

For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In combination with other medicinal products for the treatment of diabetes
SMC2273 07/09/2020 andexanet alfa (Ondexxya) Full

For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

SMC2272 07/09/2020 brolucizumab (Beovu) Full

For the treatment of neovascular (wet) age-related macular degeneration (wAMD).

SMC2262 07/09/2020 cannabidiol (Epidyolex) Full

As adjunctive therapy of seizures associated with  Dravet syndrome (DS) in conjunction with clobazam, for patients 2 years of age and older.

SMC2263 07/09/2020 cannabidiol (Epidyolex) Full

As adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) in conjunction with clobazam, for patients 2 years of age and older.

SMC2266 07/09/2020 caplacizumab (Cablivi) Full

For the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

SMC2261 07/09/2020 ex vivo expanded autologous human corneal epithelial cells containing stem cells (Holoclar) Full

For the treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity) due to physical or chemical ocular burns. A minimum of 1-2 mm2 of undamaged limbus is required for biopsy.

SMC2258 07/09/2020 esketamine (Spravato) Full

In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

SMC2260 07/09/2020 fluocinolone acetonide (Iluvien) Full

For prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Load more
Publication due date SMC meeting date Medicine Submission Type Indication
09/11/2020 06/10/2020 romosozumab (Evenity) Full

Treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

09/11/2020 06/10/2020 patiromer (Veltassa) Resubmission

For the treatment of hyperkalaemia in adults.

09/11/2020 06/10/2020 atezolizumab (Tecentriq) Full

In combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer.

09/11/2020 06/10/2020 volanesorsen sodium (Waylivra) Ultra-orphan initial assessment

As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

09/11/2020 06/10/2020 trabectedin (Yondelis) Resubmission

Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.  Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

07/12/2020 03/11/2020 mexiletine (Namuscla) Resubmission

Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.

07/12/2020 03/11/2020 bempedoic acid (Nilemdo) Full

In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin; or,
  • alone or in combination wtih other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statis is contraindicated.
07/12/2020 03/11/2020 venetoclax (Venclyxto) Full

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

07/12/2020 03/11/2020 trastuzumab emtansine (Kadcyla) Full

As a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and / or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.

11/01/2021 01/12/2020 daratumumab (Darzalex) Full

In combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

11/01/2021 01/12/2020 entrectinib (Rozlytrek) Full

For the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors.

11/01/2021 01/12/2020 entrectinib (Rozlytrek) Full

For the treatment of adult and paediatric patients 12 years of age and older, with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion:

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have not received a prior NTRK inhibitor
  • who have no satisfactory treatment options
11/01/2021 01/12/2020 fostamatinib (Tavlesse) Full

Treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.

11/01/2021 01/12/2020 melatonin (Slenyto) Resubmission

For the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

11/01/2021 01/12/2020 secukinumab (Cosentyx) Full

For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

08/02/2021 12/01/2021 ozanimod (Zeposia) Full

For adult patients with relapsing remitting multiple sclerosis.

08/02/2021 12/01/2021 upadacitinib (Rinvoq) Full

For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

12/04/2021 02/03/2021 galcanezumab (Emgality) Full

Prophylaxis of migraine in adults who have at least 4 migraine days per month

Q4 2020 Q4 2020 atezolizumab (Tecentriq) Full

In combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥  1% and who have not received prior chemotherapy for metastatic disease.

Q1 2021 Q1 2021 ravulizumab (Ultomiris) Full

For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):
• in patients with haemolysis with clinical symptom(s) indicative of high disease activity
• in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.

Load more